Norwegian Institute of Public Health, PO Box 4404 Nydalen, N-0403 Oslo, Norway.
Eur Respir J. 2010 Jun;35(6):1235-42. doi: 10.1183/09031936.00192408. Epub 2010 Jan 14.
The objective of the present study was to quantify the relationship between body mass index (BMI; in kilogrammes per metre squared) and asthma in middle-aged males and females, and to evaluate change in BMI as a risk factor for asthma. Asthma incidence was estimated from data on redeemed prescriptions of anti-asthmatic drugs during the period 2004-2007, retrieved from the nationwide Norwegian Prescription Database. BMI was measured during health surveys in 1994-1999 in >100,000 individuals born during 1952-1959. Change in BMI was based on self-report. Relative risks were estimated using Poisson regression. The relative risk associated with a 3-unit increase in BMI ranged from 1.14 (95% confidence interval 1.10-1.18) in current smokers to 1.27 (1.22-1.32) in never-smokers after adjusting for confounders. The relative risk associated with a 3-unit increase in BMI was 1.21 (1.16-1.26) after adjusting for confounders, including sex, smoking and BMI. Asthma incidence, as measured by anti-asthmatic drug use, was positively related to both BMI and change in BMI. For BMI, the association was stronger for never-smokers than for ex-smokers and current smokers.
本研究的目的是量化体重指数（BMI；以千克/平方米为单位）与中年男性和女性哮喘之间的关系，并评估 BMI 的变化是否是哮喘的一个风险因素。哮喘的发病率是根据 2004 年至 2007 年期间从全国性挪威处方数据库中检索到的抗哮喘药物处方的使用情况来估计的。BMI 是在 1994 年至 1999 年期间的健康调查中对 10 多万 1952 年至 1959 年出生的个体进行测量的。BMI 的变化是基于自我报告的。相对风险使用泊松回归估计。在校正混杂因素后，与 BMI 增加 3 个单位相关的相对风险范围为：当前吸烟者为 1.14（95%置信区间 1.10-1.18），从不吸烟者为 1.27（1.22-1.32）。在校正混杂因素，包括性别、吸烟和 BMI 后，与 BMI 增加 3 个单位相关的相对风险为 1.21（1.16-1.26）。通过使用抗哮喘药物来衡量哮喘发病率与 BMI 和 BMI 的变化均呈正相关。对于 BMI，从不吸烟者的相关性强于前吸烟者和当前吸烟者。
